 |
 |
 |
 |
 |
Treatment Name: |
 |
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
|
 |
 |
 |
 |
Phase: |
 |
Phase 1 |
 |
 |
 |
 |
 |
 |
Treatment ID#: |
 |
1871 |
 |
 |
 |
 |
Age Group: |
 |
Adults Only |
 |
 |
 |
 |
 |
 |
Min Karnofsky Score: |
 |
Not Specified |
 |
 |
 |
 |
Conditions: |
 |
Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed |
 |
 |
 |
 |
 |
 |
Last Updated: |
 |
10/09/2008 |
 |
 |
 |
 |
Tumor Types: |
 |
Anaplastic Astrocytoma Any Malignant Brain Tumor Glioblastoma Multiforme Gliosarcoma |
 |
 |
 |
 |
 |
 |
 |
Comments: |
 |
Taxol is a drug that is effective for many cancers including breast and lung to name two. It works very well at killing brain tumor cells in a dish, but lacks the ability to get across the blood brain barrier to work effectively in patients. This study utilizes a 15 amnio acid peptide which is a ligand for a receptor that actively transports across the blood brain barrier, as well as into certain tumor cells like glioblastoma. The peptide has three molecules of taxol conjugated. |
 |
 |
 |
 |
 |
 |
Treatment Type: |
 |
Chemotherapy |
 |
 |
 |
 |
Contact: |
 |
David Schiff MD Co-Director, Division of Neuro-Oncology University of Virginia Health System Department of Neurology Box 800432 Charlottesville, VA 22908-0432 USA Phone: 434-982-4415 Fax: 434-982-4467 E-mail: ds4jd@virginia.EDU Website: www.uvabraintumor.com |
 |
 |